Left ventricular hypertrophy causes: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) |
Ochuko Ajari (talk | contribs) |
||
| Line 141: | Line 141: | ||
*[[Alcoholic cardiomyopathy]] | *[[Alcoholic cardiomyopathy]] | ||
*[[Amyloidosis]] | *[[Amyloidosis]] | ||
*[[anabolic steroid detailed information|Androgenic anabolic steroid abuse]] | *[[Anderson-Fabry disease]]<ref name="pmid23448451">{{cite journal| author=Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G| title=Anderson-Fabry disease: a multiorgan disease. | journal=Curr Pharm Des | year= 2013 | volume= 19 | issue= 33 | pages= 5974-96 | pmid=23448451 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23448451 }} </ref><ref name="pmid22767366">{{cite journal| author=Cauti FM, O'Mahony C, Pantazis A| title=Cardiac involvement in Anderson-Fabry disease. | journal=BMJ Case Rep | year= 2010 | volume= 2010 | issue= | pages= | pmid=22767366 | doi=10.1136/bcr.02.2010.2760 | pmc=PMC3029827 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22767366 }} </ref> | ||
*[[Anthracyclines]] | *[[anabolic steroid detailed information|Androgenic anabolic steroid abuse]]<ref name="pmid20020375">{{cite journal| author=Vanberg P, Atar D| title=Androgenic anabolic steroid abuse and the cardiovascular system. | journal=Handb Exp Pharmacol | year= 2010 | volume= | issue= 195 | pages= 411-57 | pmid=20020375 | doi=10.1007/978-3-540-79088-4_18 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20020375 }} </ref> | ||
*[[Anthracyclines]]<ref name="pmid15095572">{{cite journal| author=Mladosievicová B| title=[ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics]. | journal=Ceska Slov Farm | year= 2004 | volume= 53 | issue= 2 | pages= 55-60 | pmid=15095572 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15095572 }} </ref> | |||
*[[Aortic insufficiency]] | *[[Aortic insufficiency]] | ||
*[[Aortic stenosis]] | *[[Aortic stenosis]] | ||
*[[Athlete's heart]] | *[[Athlete's heart]]<ref name="pmid21138810">{{cite journal| author=Pavlik G, Major Z, Varga-Pintér B, Jeserich M, Kneffel Z| title=The athlete's heart Part I (Review). | journal=Acta Physiol Hung | year= 2010 | volume= 97 | issue= 4 | pages= 337-53 | pmid=21138810 | doi=10.1556/APhysiol.97.2010.4.1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21138810 }} </ref> | ||
*[[Autosomal dominant polycystic kidney disease]] | *[[Autosomal dominant polycystic kidney disease]]<ref name="pmid21189426">{{cite journal| author=Masoumi A, Elhassan E, Schrier RW| title=Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications. | journal=Iran J Kidney Dis | year= 2011 | volume= 5 | issue= 1 | pages= 1-8 | pmid=21189426 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21189426 }} </ref><ref name="pmid16669974">{{cite journal| author=Schrier RW| title=Optimal care of autosomal dominant polycystic kidney disease patients. | journal=Nephrology (Carlton) | year= 2006 | volume= 11 | issue= 2 | pages= 124-30 | pmid=16669974 | doi=10.1111/j.1440-1797.2006.00535.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16669974 }} </ref> | ||
*[[Chronic renal failure]] | *[[Chronic renal failure]]<ref name="pmid7633909">{{cite journal| author=Gonsorcík J, Palko S, Mydlík M| title=[Cardiologic management in patients on a long-term dialysis program]. | journal=Bratisl Lek Listy | year= 1995 | volume= 96 | issue= 1 | pages= 47-50 | pmid=7633909 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7633909 }} </ref> | ||
*[[Coarctation of the aorta]] | *[[Coarctation of the aorta]] | ||
*[[Congenital heart disease]] | *[[Congenital heart disease]] | ||
*[[Danon disease]] | *[[Danon disease]] | ||
*[[Dilated cardiomyopathy]] | *[[Dilated cardiomyopathy]] | ||
*[[End stage renal disease]] | *[[End stage renal disease]] <ref name="pmid24166468">{{cite journal| author=Hammer F, Krane V, Störk S, Röser C, Hofmann K, Pollak N et al.| title=Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). | journal=Nephrol Dial Transplant | year= 2014 | volume= 29 | issue= 2 | pages= 400-5 | pmid=24166468 | doi=10.1093/ndt/gft409 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24166468 }} </ref><ref name="pmid15834618">{{cite journal| author=Groothoff JW| title=Long-term outcomes of children with end-stage renal disease. | journal=Pediatr Nephrol | year= 2005 | volume= 20 | issue= 7 | pages= 849-53 | pmid=15834618 | doi=10.1007/s00467-005-1878-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15834618 }} </ref> | ||
*[[Fabry's disease]] | *[[Fabry's disease]]<ref name="pmid24640811">{{cite journal| author=Mahmud HM| title=Fabry's disease--a comprehensive review on pathogenesis, diagnosis and treatment. | journal=J Pak Med Assoc | year= 2014 | volume= 64 | issue= 2 | pages= 189-94 | pmid=24640811 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24640811 }} </ref><ref name="pmid19069157">{{cite journal| author=Uyama E| title=[Fabry disease in light of recent review]. | journal=Brain Nerve | year= 2008 | volume= 60 | issue= 11 | pages= 1235-44 | pmid=19069157 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19069157 }} </ref> | ||
*[[Familial dilated and hypertrophic cardiomyopathy]] | *[[Familial dilated and hypertrophic cardiomyopathy]] | ||
*[[Friedreich's ataxia]] | *[[Friedreich's ataxia]] | ||
{{col-break|width=33%}} | {{col-break|width=33%}} | ||
*[[Hemochromatosis]] | *[[Hemochromatosis]] | ||
*[[Hypertension]] | *[[Hypertension]]<ref name="pmid15336807">{{cite journal| author=Passino C, Franzoni F, Gabutti A, Poletti R, Galetta F, Emdin M| title=Abnormal ventricular repolarization in hypertensive patients: role of sympatho-vagal imbalance and left ventricular hypertrophy. | journal=Int J Cardiol | year= 2004 | volume= 97 | issue= 1 | pages= 57-62 | pmid=15336807 | doi=10.1016/j.ijcard.2003.07.029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15336807 }} </ref> | ||
*[[Hypertrophic cardiomyopathy]] | *[[Hypertrophic cardiomyopathy]] <ref name="pmid23500286">{{cite journal| author=Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA et al.| title=Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. | journal=J Am Coll Cardiol | year= 2013 | volume= 61 | issue= 14 | pages= 1527-35 | pmid=23500286 | doi=10.1016/j.jacc.2013.01.037 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23500286 }} </ref> | ||
*[[Hypertrophic obstructive cardiomyopathy]] | *[[Hypertrophic obstructive cardiomyopathy]] | ||
*[[Idiopathic dilated cardiomyopathy]] | *[[Idiopathic dilated cardiomyopathy]] | ||
| Line 166: | Line 167: | ||
*[[Myocardial ischemia]] | *[[Myocardial ischemia]] | ||
*[[Noonan syndrome]] | *[[Noonan syndrome]] | ||
*[[Obesity]] | *[[Obesity]]<ref name="pmid8362892">{{cite journal| author=Alpert MA, Hashimi MW| title=Obesity and the heart. | journal=Am J Med Sci | year= 1993 | volume= 306 | issue= 2 | pages= 117-23 | pmid=8362892 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8362892 }} </ref> | ||
*[[Patent ductus arteriosus]] | *[[Patent ductus arteriosus]] | ||
*[[Pompe's disease]] | *[[Pompe's disease]] | ||
| Line 174: | Line 175: | ||
*[[Systemic hypertension]] | *[[Systemic hypertension]] | ||
*[[Thalassemia]] | *[[Thalassemia]] | ||
*[[Thyroxine]] | *[[Thyroxine]]<ref name="pmid8862963">{{cite journal| author=Bartalena L, Bogazzi F, Martino E| title=Adverse effects of thyroid hormone preparations and antithyroid drugs. | journal=Drug Saf | year= 1996 | volume= 15 | issue= 1 | pages= 53-63 | pmid=8862963 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8862963 }} </ref> | ||
*[[Tricuspid atresia]] | *[[Tricuspid atresia]] | ||
{{col-end}} | {{col-end}} | ||
Revision as of 17:34, 12 November 2014
|
Left ventricular hypertrophy Microchapters |
|
Differentiating Left ventricular hypertrophy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Left ventricular hypertrophy On the Web |
|
American Roentgen Ray Society Images of Left ventricular hypertrophy |
|
Directions to Hospitals Treating Left ventricular hypertrophy |
|
Risk calculators and risk factors for Left ventricular hypertrophy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]
Synonyms and keywords: LVH
Overview
Disease processes that can cause LVH include any disease that increases the afterload in which the heart has to contract against e.g. hypertension. Some primary diseases of the heart muscle can also give rise to left ventricular hypertrophy known as hypertrophic cardiomyopathies.
Causes
Life Threatening Causes
Common Causes
Causes by Organ System
| Cardiovascular | No underlying causes |
| Chemical/Poisoning | No underlying causes |
| Dental | No underlying causes |
| Dermatologic | No underlying causes |
| Drug Side Effect | No underlying causes |
| Ear Nose Throat | No underlying causes |
| Endocrine | No underlying causes |
| Environmental | No underlying causes |
| Gastroenterologic | No underlying causes |
| Genetic | No underlying causes |
| Hematologic | No underlying causes |
| Iatrogenic | No underlying causes |
| Infectious Disease | No underlying causes |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | No underlying causes |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | No underlying causes |
| Oncologic | No underlying causes |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | No underlying causes |
| Pulmonary | No underlying causes |
| Renal/Electrolyte | No underlying causes |
| Rheumatology/Immunology/Allergy | No underlying causes |
| Sexual | No underlying causes |
| Trauma | No underlying causes |
| Urologic | No underlying causes |
| Miscellaneous | No underlying causes |
Causes in Alphabetical Order
References
- ↑ Brush JE, Brand DA, Acampora D, Chalmer B, Wackers FJ (1985). "Use of the initial electrocardiogram to predict in-hospital complications of acute myocardial infarction". N Engl J Med. 312 (18): 1137–41. doi:10.1056/NEJM198505023121801. PMID 3920520.
- ↑ Fesmire FM, Percy RF, Wears RL (1991). "Diagnostic and prognostic importance of comparing the initial to the previous electrocardiogram in patients admitted for suspected acute myocardial infarction". South Med J. 84 (7): 841–6. PMID 2068623.
- ↑ Lazutin VK, Nychkina TN, Litvintsev VP, Iakovlev SV, Boĭko SE (1991). "[Clinical significance of arrhythmia in patients with hypertension]". Kardiologiia. 31 (4): 71–4. PMID 2067187.
- ↑ Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G (2013). "Anderson-Fabry disease: a multiorgan disease". Curr Pharm Des. 19 (33): 5974–96. PMID 23448451.
- ↑ Cauti FM, O'Mahony C, Pantazis A (2010). "Cardiac involvement in Anderson-Fabry disease". BMJ Case Rep. 2010. doi:10.1136/bcr.02.2010.2760. PMC 3029827. PMID 22767366.
- ↑ Vanberg P, Atar D (2010). "Androgenic anabolic steroid abuse and the cardiovascular system". Handb Exp Pharmacol (195): 411–57. doi:10.1007/978-3-540-79088-4_18. PMID 20020375.
- ↑ Mladosievicová B (2004). "[ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics]". Ceska Slov Farm. 53 (2): 55–60. PMID 15095572.
- ↑ Pavlik G, Major Z, Varga-Pintér B, Jeserich M, Kneffel Z (2010). "The athlete's heart Part I (Review)". Acta Physiol Hung. 97 (4): 337–53. doi:10.1556/APhysiol.97.2010.4.1. PMID 21138810.
- ↑ Masoumi A, Elhassan E, Schrier RW (2011). "Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications". Iran J Kidney Dis. 5 (1): 1–8. PMID 21189426.
- ↑ Schrier RW (2006). "Optimal care of autosomal dominant polycystic kidney disease patients". Nephrology (Carlton). 11 (2): 124–30. doi:10.1111/j.1440-1797.2006.00535.x. PMID 16669974.
- ↑ Gonsorcík J, Palko S, Mydlík M (1995). "[Cardiologic management in patients on a long-term dialysis program]". Bratisl Lek Listy. 96 (1): 47–50. PMID 7633909.
- ↑ Hammer F, Krane V, Störk S, Röser C, Hofmann K, Pollak N; et al. (2014). "Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa)". Nephrol Dial Transplant. 29 (2): 400–5. doi:10.1093/ndt/gft409. PMID 24166468.
- ↑ Groothoff JW (2005). "Long-term outcomes of children with end-stage renal disease". Pediatr Nephrol. 20 (7): 849–53. doi:10.1007/s00467-005-1878-9. PMID 15834618.
- ↑ Mahmud HM (2014). "Fabry's disease--a comprehensive review on pathogenesis, diagnosis and treatment". J Pak Med Assoc. 64 (2): 189–94. PMID 24640811.
- ↑ Uyama E (2008). "[Fabry disease in light of recent review]". Brain Nerve. 60 (11): 1235–44. PMID 19069157.
- ↑ Passino C, Franzoni F, Gabutti A, Poletti R, Galetta F, Emdin M (2004). "Abnormal ventricular repolarization in hypertensive patients: role of sympatho-vagal imbalance and left ventricular hypertrophy". Int J Cardiol. 97 (1): 57–62. doi:10.1016/j.ijcard.2003.07.029. PMID 15336807.
- ↑ Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA; et al. (2013). "Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy". J Am Coll Cardiol. 61 (14): 1527–35. doi:10.1016/j.jacc.2013.01.037. PMID 23500286.
- ↑ Alpert MA, Hashimi MW (1993). "Obesity and the heart". Am J Med Sci. 306 (2): 117–23. PMID 8362892.
- ↑ Bartalena L, Bogazzi F, Martino E (1996). "Adverse effects of thyroid hormone preparations and antithyroid drugs". Drug Saf. 15 (1): 53–63. PMID 8862963.